首页> 外文OA文献 >Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can

【2h】

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can

机译：生活质量结果包括来自II期的神经病理相关规模，来自二期的Eribulin Plus Gemcitabine与PACLitaxel Plus Gemcitabine作为Her2阴性转移乳腺癌的一线化疗：韩国人

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Ji-Yeon Kim; Seri Park; Seock-Ah Im; Sung-Bae Kim; Joohyuk Sohn; Keun Seok Lee; Yee Soo Chae; Ki Hyeong Lee; Jee Hyun Kim; Young-Hyuck Im; Tae-Yong Kim; Kyung-Hun Lee; Jin-Hee Ahn; Gun Min Kim; In Hae Park; Soo Jung Lee; Hye Sook Han; Se Hyun Kim; Kyung Hae Jung; Yeon Hee Park;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) [J] . Ji-Yeon Kim, Seri Park, Seock-Ah Im, Cancer Communications . 2019,第1期

机译：生活质量结果包括来自II期的神经病症相关规模，来自二期的Eribulin Plus Gemcitabine的多中心，随机试验与紫杉醇加吉西他滨作为Her2阴性转移乳腺癌的一线化疗：韩国癌症研究组试验（KCSG BR13-11）
3. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer [J] . Park Yeon Hee, Im Seock-Ah, Kim Sung-Bae, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：II期，MultiSclin，Eribulin的随机试验，吉西他滨与紫杉醇加吉西他滨，作为Her2阴性转移性乳腺癌患者的一线化学疗法
4. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02) [J] . Park Yeon Hee, Jung Kyung Hae, Im Seock-Ah, Breast cancer research and treatment. . 2015,第1期

机译：维持性紫杉醇联合吉西他滨（PG）化疗的转移性乳腺癌患者的生活质量（QoL）：Ⅲ期，多中心，维持性化疗与观察性随机对照试验的结果（KCSG-BR07-02）
5. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
6. Enhancement of Gemcitabine and Paclitaxel Uptake and Retention in Metastatic Cancer Cells: A Novel Targeted Combination Delivery Approach to Eliminate Breast Cancer in Blood and Lymph [D] . Yu, Jesse. 2020

机译：吉西他滨和紫杉醇吸收的增强和转移性癌细胞的保留：一种小型靶向组合递送方法，消除血液和淋巴中的乳腺癌
7. Quality of life outcomes including neuropathy-associated scale from a phase II multicenter randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) [O] . Ji-Yeon Kim, Seri Park, Seock-Ah Im, 2019

机译：生活质量的结果包括II期多中心埃瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的神经病相关评分的随机临床试验：韩国癌症研究小组试验（KCSG BR13-11）
8. Erratum to: ‘Phase II/III weekly -paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial [O] . 2016

机译：勘误：‘每周II / III期-紫杉醇加吉西他滨或卡铂与吉西他滨/卡铂作为转移性三阴性乳腺癌患者的一线治疗（tnAcity研究）：一项随机对照试验的研究方案

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can

著录项

相似文献

相关主题

期刊订阅